[Application of biomarkers in predicting cardiotoxicity induced by antitumor therapy]

Q X Li; Y Ouyang; X Hu; H He; J F Hu; Y Zhou

doi:10.3760/cma.j.cn112148-20241028-00650

[Application of biomarkers in predicting cardiotoxicity induced by antitumor therapy]

Zhonghua Xin Xue Guan Bing Za Zhi. 2025 Jan 24;53(1):80-86. doi: 10.3760/cma.j.cn112148-20241028-00650.

[Article in Chinese]

Authors

Q X Li¹, Y Ouyang¹, X Hu², H He³, J F Hu², Y Zhou²

Affiliations

¹ Department of Pharmacy, the First Affiliated Hospital of Nanchang University, Nanchang330006, China School of Pharmacy, Nanchang University, Nanchang330006, China.
² Department of Pharmacy, the First Affiliated Hospital of Nanchang University, Nanchang330006, China.
³ School of Pharmacy, China Pharmaceutical University, Nanjing210009, China.

PMID: 39806909
DOI: 10.3760/cma.j.cn112148-20241028-00650

Abstract

抗肿瘤治疗技术的创新和发展极大地提高了各类恶性肿瘤患者的生存率，与此同时，越来越多的患者出现与抗肿瘤治疗相关的心脏毒性。生物标志物是患者进行心血管疾病基线风险评估和诊断的重要辅助工具，已有不少临床研究证明，生物标志物可以预测抗肿瘤治疗后的早期心脏毒性。该文对生物标志物在预测抗肿瘤治疗诱发心脏毒性中的应用进行归纳总结和分析。.

Publication types

Review

MeSH terms

Antineoplastic Agents* / adverse effects
Biomarkers*
Cardiotoxicity* / diagnosis
Cardiotoxicity* / etiology
Humans
Neoplasms / drug therapy

Substances

Biomarkers
Antineoplastic Agents